|
Home | Medical-Newswire.Com:
|
(Medical-NewsWire.com, October 23, 2012 ) New York, NY -- Sunshine Heart (SSH) shares were moving higher on Monday, trading up by five percent after having dropped to near the six dollar mark late last week following the airing of funding concerns on the Seeking Alpha website by an individual investor who held no position in the stock.
VFC's Stock House, an information and research outlet that brings ideas and opens discussions to a broad spectrum of investors, highlights Sunshine Heart as a stock in the spotlight on Tuesday at http://VFCsStockHouse.com
The investor concerns, as it turns out, may have been a tad bit overblown as they did not address the fact that the C-Pulse Heart Assist system had already received a CE Mark approval in Europe and is on track to start registering commercial sales as soon as within the current quarter.
Additional concerns were raised - and then debunked - regarding competition from other heart-assist devices on the market, specifically those marketed by Heartware International (HTWR) and Thoratec (THOR), for example, given that the C-Pulse is implanted outside of a patient's bloodstream, a huge advantage over any purported competition.
Investors digesting this news may have led the SSH rebound charge, but Sunshine is also receiving attention this week by presenting at the 24th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium in Miami, Florida. Data from the already-completed feasibility study will be presented, including a 12-month follow-up of patients utilizing the C-Pulse.
Also of note, Sunshine received Frost & Sullivan's '2012 North American Heart Failure Treatment New Product Innovation Award' for C-Pulse this week, another potential factor in Monday's share price rise.
C-Pulse, in addition to other supporting factors, received the award due to the device's "novel" qualities of being implanted outside of the bloodstream. Venkat Rajan, Industry Manager for Medical Devices at Frost & Sullivan, noted in the associated release:
"Capable of delivering treatment without contact of blood, the implantable C-Pulse Heart Assist system represents a truly novel approach into the treatment paradigm for heart failure patient."
C-Pulse also recently received an Investigational Device Exemption (IDE) by the FDA that clears the way for development in the US. A pivotal trial in the United States is also expected to commence within the current quarter with an eye towards FDA approval. On a funding note, a recent round of financing has positioned the company on sound footing until the mid-way point of this trial, at which time a potential partner could come in and make a move. The idea of a partner coming on board - or the company being outright purchased - may not be so far-fetched, considering that the recent financing deal included a multi-million dollar up-front payment by a "strategic investor" who will also send a member to Sunshine's board.
Such moves strongly hint at partnership or buyout interest.
Volume was light during Monday's run, but SSH will be receiving additional attention this week, given the presentations in Florida and the innovation award.
Disclosure: Long SSH.
Follow the developments of SSH and other small cap stocks at VFCsStockHouse.com
Contact VFC's Stock House: vfc@vfcsstockhouse.com
Follow VFC's Stock House on Twitter: https://twitter.com/#!/VFCsStockHouse
'Like' VFC's Stock House on Facebook: http://www.facebook.com/pages/VFCs-Stock-House/143724412345213
About VFCsStockHouse.com: VFC's Stock House is an information and research outlet that brings new ideas to the table and opens discussions for a broad spectrum of investors, with a strong focus on - but not limited to - biotech stocks, biopharma stocks, and pharmaceutical and healthcare stocks. VFC's Stock House provides individual company profiles, write-ups and reports as well as giving general insights into broader-market news through various 'Stock Watch' lists. At the conclusion of most weeks, VFC's Stock House issues a "Weekly Stock Watch" that examines news items, stocks and stories that made headlines during the previous trading week, but may also make headlines or influence trends during the upcoming week as well. The information contained within the pages of VFC’s Stock House are not intended to be taken as advice, but as a starting point where investors can follow up with their own DD and devise their own entry and exit strategies.
For full disclaimer visit: http://vfcsstockhouse.com
VFC's Stock House
VFC
240-786-2111
vfc@vfcsstockhouse.com
Source: EmailWire.Com 
Source: EmailWire.com
|
|
|
|
